Pancreatic Cancer Research

ResearcherFukushima Medical UniversityActive in the last 2 years

Mitsuru Sugimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4223-613X; OpenAlex author ID A5029055634. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: 5 papers

Papers 19

  1. Prediction model for mutation detection via circulating tumor DNA analysis in pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.09.003↗
  2. A Systemic Review and Meta-analysis of the Incidence Rate of Interstitial Lung Disease in Patients with Unresectable Pancreatic Cancer Treated with Gemcitabine… Co-author DOI 10.2169/internalmedicine.5084-24↗
  3. Prediction System for KRAS Mutation Detection in Circulating Tumor DNA in Unresectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17751↗
  4. Development and Validation of a Nomogram of Predict Eligibility for Second-line Chemotherapy in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17798↗
  5. Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan. Co-author DOI 10.5387/fms.24-00011↗
  6. Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from … Co-author DOI 10.1186/s12885-023-10781-x↗
  7. A multicenter comparative study of endoscopic ultrasound-guided fine-needle biopsy using a Franseen needle versus conventional endoscopic ultrasound-guided fin… First author DOI 10.5946/ce.2022.019↗
  8. The Complement C3a-C3a Receptor Axis Regulates Epithelial-to-Mesenchymal Transition by Activating the ERK Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15587↗
  9. Intracellular C3 Modulates EMT via the Akt/Smad Pathway in Pancreatic Cancer Cells. Co-author DOI 10.21873/anticanres.16081↗
  10. Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer. Co-author DOI 10.5387/fms.2021-32↗
  11. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. Co-author DOI 10.1186/s12885-021-09069-9↗
  12. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospectiv… Co-author DOI 10.1007/s00280-019-03983-3↗
  13. An observation study of the prognostic effect of waiting times in the management of pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2018.9626↗
  14. Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.23377↗
  15. Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy. Co-author DOI 10.3892/mco.2018.1696↗
  16. Endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. Co-author DOI 10.5387/fms.2018-14↗
  17. Contrast-enhanced harmonic endoscopic ultrasonography in gallbladder cancer and pancreatic cancer. Co-author DOI 10.5387/fms.2017-04↗
  18. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2016.09.003↗
  19. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Co-author DOI 10.3892/ol.2016.4381↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromasa Ohira · 19 shared papers, 2016–2025 · strength 2.59
  2. Rei Suzuki · 17 shared papers, 2016–2025 · strength 2.13
  3. Tadayuki J. Takagi · 17 shared papers, 2016–2025 · strength 2.10
  4. Hiroyuki Asama · 14 shared papers, 2016–2025 · strength 2.04
  5. Hiroki Irie · 11 shared papers, 2018–2025 · strength 1.54
  6. Hiroshi Shimizu · 5 shared papers, 2025 · strength 1.17
  7. Kentaro Sato · 5 shared papers, 2025 · strength 1.17
  8. Rei Ohira · 4 shared papers, 2025 · strength 0.94
  9. Yuichi Waragai · 6 shared papers, 2016–2025 · strength 0.69
  10. Rei Suzuki · 2 shared papers, 2025 · strength 0.46
  11. Shigeru Marubashi · 3 shared papers, 2018–2023 · strength 0.30
  12. Atsushi Masamune · 2 shared papers, 2016–2018 · strength 0.12
  13. Ya’an Kang · 1 shared paper, 2016 · strength 0.05
  14. Jason B. Fleming · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.